Alpha Tau to Host Conference Call for Interim Glioblastoma Trial Results

summarizeSummary

Alpha Tau Medical announced it will host a conference call to discuss interim clinical data from the first three patients in its U.S. REGAIN trial for recurrent glioblastoma, signaling upcoming insights into its Alpha DaRT therapy for this challenging cancer.

check_boxKey Events

• Conference Call Scheduled

  Alpha Tau Medical will host a conference call and webcast on Monday, May 11, 2026, at 8:30 AM ET.

• Focus on Glioblastoma Trial

  The call will discuss interim clinical data from the first three patients treated in its U.S. REGAIN trial for recurrent glioblastoma (GBM).

• Interim Data from Early Patients

  The REGAIN study aims to evaluate the feasibility and safety of the Alpha DaRT treatment in up to ten U.S. patients with recurrent glioblastoma not amenable to surgical resection.

auto_awesomeAnalysis

Alpha Tau Medical's announcement of a conference call to discuss interim clinical data from its U.S. REGAIN trial for recurrent glioblastoma is a significant event. Glioblastoma is an aggressive and difficult-to-treat brain cancer with high unmet medical need, making any progress in treatment highly impactful. While this filing only announces the call, the decision to host a dedicated event for interim results from the first three patients suggests the company anticipates sharing encouraging data. This follows a series of positive clinical updates from Alpha Tau, indicating active development and potential for its Alpha DaRT therapy in challenging oncology indications. Investors will closely watch the upcoming call for insights into the therapy's safety and efficacy in this critical patient population.